InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,344.39
(
0.00%
)
US TECH 100
18,066.40
(
0.28%
)
Dow Jones
39,357.01
(
-0.36%
)
Brent Oil
81.30
(
-0.38%
)
Bitcoin
59,124.72
(
-0.39%
)
Post# of 252864
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 835
Posts 120262
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: 10nisman post# 111373

Thursday, 02/10/2011 7:36:29 PM

Thursday, February 10, 2011 7:36:29 PM

Post# of 252864
Teva’s ‘low-volume’ Copaxone will almost certainly not be brought to market. The subject came up at Teva’s NY luncheon for analysts yesterday and Bill Marth’s reply was that “the future of the program is being debated inside Teva” and that it’s unclear whether the prospects warrant conducting the large safety and efficacy study the FDA demanded as a condition for approval. This is biotech-speak for saying that the program is dead.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up